Envy Medical is one of the most exciting medical technology companies to emerge in the field of dermatology and medical aesthetics. Founded by Ken Karasiuk, the Company flourished on the 2002 patented invention of Dermalinfusiom, method of non-invasive skin therapy, under the SilkPeel™ brand of medical devices. SilkPeel is already a gold standard for leading dermatologists and cosmetic surgeons for treating acne, hyperpigmentation, photo-damage, fine line wrinkles and minor scaring on the face and body.

The Company also owns exclusive rights to a class of novel peptides that show clinical efficacy in the topical treatment of dermatologic indications. The lead peptide, decapeptide-12 was developed by Dr. Basil Hantash’s team of dermatological researchers out of Stanford University, this ground-breaking technology encompasses the only peptide class clinically shown to significantly brighten skin, and address hyperpigmentation. In 2010, the company introduced its first product line for skin brightening under the brand name Lumixyl™. Recent studies show that Lumixyl™, provides comparable or better results than prescription hydroquinone products, and yet is completely non-cytotoxic and therefore does not result in the side effects associated with such prescription level products.


The Future of Envy Medical